Search Results

You are looking at 31 - 34 of 34 items for :

  • "treatment initiation" x
Clear All
Marie Oertel Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany

Search for other papers by Marie Oertel in
Google Scholar
PubMed
Close
,
Christian G Ziegler Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden, Dresden, Germany

Search for other papers by Christian G Ziegler in
Google Scholar
PubMed
Close
,
Michael Kohlhaas Comprehensive Heart Failure Center, Würzburg, Germany

Search for other papers by Michael Kohlhaas in
Google Scholar
PubMed
Close
,
Alexander Nickel Comprehensive Heart Failure Center, Würzburg, Germany

Search for other papers by Alexander Nickel in
Google Scholar
PubMed
Close
,
Simon Kloock Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany

Search for other papers by Simon Kloock in
Google Scholar
PubMed
Close
,
Christoph Maack Comprehensive Heart Failure Center, Würzburg, Germany

Search for other papers by Christoph Maack in
Google Scholar
PubMed
Close
,
Vasco Sequeira Comprehensive Heart Failure Center, Würzburg, Germany

Search for other papers by Vasco Sequeira in
Google Scholar
PubMed
Close
,
Martin Fassnacht Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany

Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Close
, and
Ulrich Dischinger Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Würzburg, Würzburg, Germany
Comprehensive Heart Failure Center, Würzburg, Germany

Search for other papers by Ulrich Dischinger in
Google Scholar
PubMed
Close

intervals within the delivery time of the osmotic minipumps (42 days) for all treatment groups. At the time of treatment initiation, all treatment groups (starting at different time points) had comparable body weights (567 ± 48 g for group 1, 576 ± 6 g for

Open access
Pernille H Hellmann Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Pernille H Hellmann in
Google Scholar
PubMed
Close
,
Jonatan I Bagger Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Jonatan I Bagger in
Google Scholar
PubMed
Close
,
Katrine R Carlander Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Katrine R Carlander in
Google Scholar
PubMed
Close
,
Katrine B Hansen Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Katrine B Hansen in
Google Scholar
PubMed
Close
,
Julie L Forman Section of Biostatistics, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Julie L Forman in
Google Scholar
PubMed
Close
,
Joachim Størling Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Joachim Størling in
Google Scholar
PubMed
Close
,
Elizaveta Chabanova Department of Radiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Elizaveta Chabanova in
Google Scholar
PubMed
Close
,
Jens Holst Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Jens Holst in
Google Scholar
PubMed
Close
,
Tina Vilsbøll Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
Close
, and
Filip K Knop Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Clinical Research, Steno Diabetes Center Copenhagen, Herlev, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Filip K Knop in
Google Scholar
PubMed
Close

Parameters calculated from data recorded from 8:00 h at the day of prednisolone/prednisolone placebo treatment initiation until second magnetic resonance spectroscopy or the night before experimental day #2 whichever came first. b Welch two-sample t test. CV

Open access
Charlotte Höybye Department of Endocrinology and Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden

Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Close
,
Beverly M K Biller Neuroendocrine Unit, Massachusetts General Hospital, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Close
,
Jean-Marc Ferran Qualiance ApS, Copenhagen, Denmark

Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed
Close
,
Murray B Gordon Allegheny Neuroendocrinology Center, Division of Endocrinology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA

Search for other papers by Murray B Gordon in
Google Scholar
PubMed
Close
,
Nicky Kelepouris US Medical Affairs-Rare Endocrine Disorders, Novo Nordisk, Inc, Plainsboro, New Jersey, USA

Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Close
,
Navid Nedjatian Global Medical Affairs – Rare Endocrine Disorders, Novo Nordisk Health Care AG, Zurich, Switzerland

Search for other papers by Navid Nedjatian in
Google Scholar
PubMed
Close
,
Anne H Olsen Epidemiology, Novo Nordisk A/S, Soborg, Denmark

Search for other papers by Anne H Olsen in
Google Scholar
PubMed
Close
, and
Matthias M Weber Unit of Endocrinology, 1, Medical Department, University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg-Universität, Mainz, Germany

Search for other papers by Matthias M Weber in
Google Scholar
PubMed
Close

patients after treatment initiation were compared with the CV risks of age- and sex-matched control groups (matched control) consisting of patients with AGHD at study enrolment of the NordiNet ® IOS or the ANSWER Program who had not yet begun GH

Open access
Merlin C Thomas Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia

Search for other papers by Merlin C Thomas in
Google Scholar
PubMed
Close
,
Brendon L Neuen The George Institute for Global Health, Sydney, NSW, Australia

Search for other papers by Brendon L Neuen in
Google Scholar
PubMed
Close
,
Stephen M Twigg The University of Sydney School of Medicine, Sydney, NSW, Australia
Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia

Search for other papers by Stephen M Twigg in
Google Scholar
PubMed
Close
,
Mark E Cooper Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia

Search for other papers by Mark E Cooper in
Google Scholar
PubMed
Close
, and
Sunil V Badve The George Institute for Global Health, Sydney, NSW, Australia
Department of Renal Medicine, St George Hospital, Sydney, NSW, Australia
Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia

Search for other papers by Sunil V Badve in
Google Scholar
PubMed
Close

prior to treatment initiation with SGLT2 inhibitors and to correct hypovolemia (particularly in elderly patients, in patients with impaired kidney function or low systolic blood pressure and in patients receiving diuretics) ( 69 , 70 , 71 , 72 ). In

Open access